ID

36677

Beschreibung

Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC).; ODM derived from: https://clinicaltrials.gov/show/NCT02453282

Link

https://clinicaltrials.gov/show/NCT02453282

Stichworte

Versionen (1)
  1. 31.05.19 31.05.19 -
Rechteinhaber

See clinicaltrials.gov

Hochgeladen am

31. Mai 2019

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0
Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Zurück zu Modell Kommentaren
Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Non-Small-Cell Lung Carcinoma (NSCLC) NCT02453282

Englisch

Eligibility Non-Small-Cell Lung Carcinoma (NSCLC) NCT02453282

1 Formulare  
Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
for inclusion in the study, patients should fulfill the following criteria:
Beschreibung

Criteria Fulfill

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0243161
UMLS CUI [1,2]
C1550543
aged at least 18 years
Beschreibung

Age

Datentyp

boolean

Alias
UMLS CUI [1]
C0001779
documented evidence of stage iv nsclc
Beschreibung

Non-Small Cell Lung Carcinoma TNM clinical staging

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0007131
UMLS CUI [1,2]
C3258246
no activating egfr mutation or alk rearrangement
Beschreibung

Activating EGFR Gene Mutation Negative | ALK Gene Rearrangement Negative

Datentyp

boolean

Alias
UMLS CUI [1]
C4525184
UMLS CUI [2]
C4525178
no prior chemotherapy or any other systemic therapy for recurrent/metastatic nsclc
Beschreibung

Prior Chemotherapy Absent Non-small cell lung cancer recurrent | Systemic therapy Absent Non-small cell lung cancer recurrent | Prior Chemotherapy Absent Non-small cell lung cancer metastatic | Systemic therapy Absent Non-small cell lung cancer metastatic

Datentyp

boolean

Alias
UMLS CUI [1,1]
C1514457
UMLS CUI [1,2]
C0332197
UMLS CUI [1,3]
C0278517
UMLS CUI [2,1]
C1515119
UMLS CUI [2,2]
C0332197
UMLS CUI [2,3]
C0278517
UMLS CUI [3,1]
C1514457
UMLS CUI [3,2]
C0332197
UMLS CUI [3,3]
C0278987
UMLS CUI [4,1]
C1515119
UMLS CUI [4,2]
C0332197
UMLS CUI [4,3]
C0278987
world health organization (who) performance status of 0 or 1
Beschreibung

WHO performance status scale

Datentyp

boolean

Alias
UMLS CUI [1]
C1298650
Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
patients should not enter the study if any of the following exclusion criteria are fulfilled:
Beschreibung

Exclusion Criteria Fulfill

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0680251
UMLS CUI [1,2]
C1550543
mixed small-cell lung cancer and nsclc histology or not otherwise specified (nsclc nos)
Beschreibung

Small cell carcinoma of lung NSCLC Mixed | NSCLC Not Otherwise Specified

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0149925
UMLS CUI [1,2]
C0007131
UMLS CUI [1,3]
C0205430
UMLS CUI [2,1]
C0007131
UMLS CUI [2,2]
C1518425
brain metastases or spinal cord compression unless asymptomatic, treated and stable (not requiring steroids)
Beschreibung

Metastatic malignant neoplasm to brain | Compression of spinal cord | Exception Metastatic malignant neoplasm to brain Asymptomatic | Exception Compression of spinal cord Asymptomatic | Exception Metastatic malignant neoplasm to brain Treated Stable | Exception Compression of spinal cord Treated Stable | Exception Steroids Redundant

Datentyp

boolean

Alias
UMLS CUI [1]
C0220650
UMLS CUI [2]
C0037926
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0220650
UMLS CUI [3,3]
C0231221
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C0037926
UMLS CUI [4,3]
C0231221
UMLS CUI [5,1]
C1705847
UMLS CUI [5,2]
C0220650
UMLS CUI [5,3]
C1522326
UMLS CUI [5,4]
C0205360
UMLS CUI [6,1]
C1705847
UMLS CUI [6,2]
C0037926
UMLS CUI [6,3]
C1522326
UMLS CUI [6,4]
C0205360
UMLS CUI [7,1]
C1705847
UMLS CUI [7,2]
C0038317
UMLS CUI [7,3]
C1313915
prior exposure to immunomodulatory therapy (imt), including, but not limited to, other anti-cytotoxic t-lymphocyte-associated antigen 4 (ctla-4), anti-programmed cell death1 (pd-1), anti-programmed cell death ligand 1 (pd-l1), or anti pd-l2 antibodies, excluding therapeutic anticancer vaccines
Beschreibung

Immunomodulation | Anti-CTLA-4 Monoclonal Antibody | Anti-PD1 Monoclonal Antibody | Anti-PD-L1 Monoclonal Antibody | PD-L2 Monoclonal Antibody | Exception Vaccine Cancer treatment

Datentyp

boolean

Alias
UMLS CUI [1]
C1963758
UMLS CUI [2]
C4289973
UMLS CUI [3]
C4289970
UMLS CUI [4]
C4289971
UMLS CUI [5,1]
C1705357
UMLS CUI [5,2]
C0003250
UMLS CUI [6,1]
C1705847
UMLS CUI [6,2]
C0042210
UMLS CUI [6,3]
C0920425
active or prior documented inflammatory bowel disease (eg, crohn's disease, ulcerative colitis)
Beschreibung

Inflammatory Bowel Disease | Crohn Disease | Ulcerative Colitis

Datentyp

boolean

Alias
UMLS CUI [1]
C0021390
UMLS CUI [2]
C0010346
UMLS CUI [3]
C0009324
Zum Seitenanfang zurückkehren

Ähnliche Modelle

Eligibility Non-Small-Cell Lung Carcinoma (NSCLC) NCT02453282

1 Formulare
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
Criteria Fulfill
Item
for inclusion in the study, patients should fulfill the following criteria:
boolean
C0243161 (UMLS CUI [1,1])
C1550543 (UMLS CUI [1,2])
Age
Item
aged at least 18 years
boolean
C0001779 (UMLS CUI [1])
Non-Small Cell Lung Carcinoma TNM clinical staging
Item
documented evidence of stage iv nsclc
boolean
C0007131 (UMLS CUI [1,1])
C3258246 (UMLS CUI [1,2])
Activating EGFR Gene Mutation Negative | ALK Gene Rearrangement Negative
Item
no activating egfr mutation or alk rearrangement
boolean
C4525184 (UMLS CUI [1])
C4525178 (UMLS CUI [2])
Prior Chemotherapy Absent Non-small cell lung cancer recurrent | Systemic therapy Absent Non-small cell lung cancer recurrent | Prior Chemotherapy Absent Non-small cell lung cancer metastatic | Systemic therapy Absent Non-small cell lung cancer metastatic
Item
no prior chemotherapy or any other systemic therapy for recurrent/metastatic nsclc
boolean
C1514457 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C0278517 (UMLS CUI [1,3])
C1515119 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
C0278517 (UMLS CUI [2,3])
C1514457 (UMLS CUI [3,1])
C0332197 (UMLS CUI [3,2])
C0278987 (UMLS CUI [3,3])
C1515119 (UMLS CUI [4,1])
C0332197 (UMLS CUI [4,2])
C0278987 (UMLS CUI [4,3])
WHO performance status scale
Item
world health organization (who) performance status of 0 or 1
boolean
C1298650 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Exclusion Criteria Fulfill
Item
patients should not enter the study if any of the following exclusion criteria are fulfilled:
boolean
C0680251 (UMLS CUI [1,1])
C1550543 (UMLS CUI [1,2])
Small cell carcinoma of lung NSCLC Mixed | NSCLC Not Otherwise Specified
Item
mixed small-cell lung cancer and nsclc histology or not otherwise specified (nsclc nos)
boolean
C0149925 (UMLS CUI [1,1])
C0007131 (UMLS CUI [1,2])
C0205430 (UMLS CUI [1,3])
C0007131 (UMLS CUI [2,1])
C1518425 (UMLS CUI [2,2])
Metastatic malignant neoplasm to brain | Compression of spinal cord | Exception Metastatic malignant neoplasm to brain Asymptomatic | Exception Compression of spinal cord Asymptomatic | Exception Metastatic malignant neoplasm to brain Treated Stable | Exception Compression of spinal cord Treated Stable | Exception Steroids Redundant
Item
brain metastases or spinal cord compression unless asymptomatic, treated and stable (not requiring steroids)
boolean
C0220650 (UMLS CUI [1])
C0037926 (UMLS CUI [2])
C1705847 (UMLS CUI [3,1])
C0220650 (UMLS CUI [3,2])
C0231221 (UMLS CUI [3,3])
C1705847 (UMLS CUI [4,1])
C0037926 (UMLS CUI [4,2])
C0231221 (UMLS CUI [4,3])
C1705847 (UMLS CUI [5,1])
C0220650 (UMLS CUI [5,2])
C1522326 (UMLS CUI [5,3])
C0205360 (UMLS CUI [5,4])
C1705847 (UMLS CUI [6,1])
C0037926 (UMLS CUI [6,2])
C1522326 (UMLS CUI [6,3])
C0205360 (UMLS CUI [6,4])
C1705847 (UMLS CUI [7,1])
C0038317 (UMLS CUI [7,2])
C1313915 (UMLS CUI [7,3])
Immunomodulation | Anti-CTLA-4 Monoclonal Antibody | Anti-PD1 Monoclonal Antibody | Anti-PD-L1 Monoclonal Antibody | PD-L2 Monoclonal Antibody | Exception Vaccine Cancer treatment
Item
prior exposure to immunomodulatory therapy (imt), including, but not limited to, other anti-cytotoxic t-lymphocyte-associated antigen 4 (ctla-4), anti-programmed cell death1 (pd-1), anti-programmed cell death ligand 1 (pd-l1), or anti pd-l2 antibodies, excluding therapeutic anticancer vaccines
boolean
C1963758 (UMLS CUI [1])
C4289973 (UMLS CUI [2])
C4289970 (UMLS CUI [3])
C4289971 (UMLS CUI [4])
C1705357 (UMLS CUI [5,1])
C0003250 (UMLS CUI [5,2])
C1705847 (UMLS CUI [6,1])
C0042210 (UMLS CUI [6,2])
C0920425 (UMLS CUI [6,3])
Inflammatory Bowel Disease | Crohn Disease | Ulcerative Colitis
Item
active or prior documented inflammatory bowel disease (eg, crohn's disease, ulcerative colitis)
boolean
C0021390 (UMLS CUI [1])
C0010346 (UMLS CUI [2])
C0009324 (UMLS CUI [3])
Zum Seitenanfang zurückkehren 

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video